Form 4: Pliant Therapeutics Chief Business Officer Sells Shares to Cover Tax Obligations

Pliant Therapeutics' Chief Business Officer, Hans Hull, sold 15,936 shares of common stock at an average price of $11.2011 to cover tax liabilities related to vesting restricted stock units.

Summary

• Hans Hull, Chief Business Officer of Pliant Therapeutics, sold 15,936 shares of common stock on January 17, 2025, at an average price of $11.2011 per share.
• The sale was executed to cover withholding tax liabilities associated with the vesting of previously granted restricted stock units.
• The shares were sold through a broker at prices ranging from $11.03 to $11.695.
• Following the transaction, Mr. Hull directly owns 211,558 shares of common stock.
• Mr. Hull also has indirect ownership of 3,821 shares through The Sloger Hull Family Trust, 13,985 shares through a trust for his minor child (Child A Trust), and 13,985 shares through a trust for his other minor child (Child B Trust).
• Mr. Hull disclaims beneficial ownership of the shares held in the trusts except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: This is a neutral event, a routine sale of shares by an executive to cover tax obligations. It doesn't indicate positive or negative sentiment about the company's prospects.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the industry.
• The sale price range of $11.03 to $11.695 is within the typical market fluctuations for a company like Pliant Therapeutics.
• Similar transactions are regularly reported by executives at comparable biotech companies.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it is a routine transaction.
• The sale does not affect the company's operations or financial health.

Key Dates

Keywords

Pliant Therapeutics, Hans Hull, stock sale, insider trading, Form 4, restricted stock units, tax liabilities, beneficial ownership